ArticleMaterials today. Bio2026
Multi-omics-guided targeting of the CD14-NF-κB axis with PGA1-loaded liposomes restores CD14
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is common in patients with rotator cuff tears (RCTs) and is associated with poor tendon-bone healing and high retear rates. Tendon stem/progenitor cells (TSPCs) are central to tendon-bone integration, but how T2DM reprograms TSPCs and whether this can be reversed remain unclear. Methods: T2DM was induced in rodents, followed by tendon single-cell RNA sequencing, serum metabolomics and tendon proteomics. TSPCs were isolated for functional assays and analysis of underlying signaling. CD14-overexpressing (CD14 Results: Multi-omics analysis revealed that T2DM induced marked remodeling of the tendon-resident cell landscape, with TSPCs exhibiting upregulated CD14 expression and enrichment of NF-κB-related inflammatory and apoptotic pathways, alongside systemic depletion of serum PGA1. Diabetic and CD14 Conclusion: T2DM reprograms tendon-resident TSPCs through a CD14-PGA1-NF-κB axis, driving apoptosis and reducing progenitor-like functional properties. Multi-omics-guided targeting of this axis with PGA1-loaded liposomes restores CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.